Listing timing unconfirmed
Last verified 23 Oct 2026The previously expected date of 15 Oct 2026 has passed. Trading has not been confirmed.
- IPO valuation
- $758.4MBasic equity value after the offering
- IPO price
- $16.00Per share · USD
- Offering size
- $150MBase offering, before overallotment
- Previously expected
- 15 Oct 2026Listing timing unconfirmed
Company overview
Iambic Therapeutics websiteThe company combines proprietary, large-scale artificial intelligence with chemistry and biology experimentation. Its experimentation is automated and scalable.
- Company country
- United States
Offering details
USD · Base offering, before overallotment
- Exchange
- Nasdaq Global Select Market
- Ticker
- IAM
- Shares offered
- 9,375,000
- Shares after offering
- 47,400,796
Valuation and offering basis
Basic equity valuation is the price per share multiplied by all shares outstanding immediately after the offering. It is different from enterprise value or fully diluted valuation. Offering size and gross proceeds exclude optional additional shares, fees and expenses. Ranges use the proposed price range; figures are rounded.
IPO timeline
- Registration filedIambic Therapeutics files for an IPO
- Proposed terms publishedIambic Therapeutics sets an IPO price range
- Proposed terms published
- Proposed terms published
- Final offer price announced
- Final offer price announced
- Proposed terms published
- Previously expected first trading day · Announced date
Filings and documents
- Pricing announcementChecked 23 Oct 2026 (undated source)View document
- View document
- Updated offering termsChecked 9 Oct 2026 (undated source)View document
- Updated offering termsChecked 9 Oct 2026 (undated source)View document
- View document
- View document
- View document
- View document